Drug Insights

Explore Digoxin on Synapse: Tips and Tricks for Better Search Results

14 March 2024
2 min read

Digoxin, a diminutive molecular compound, has garnered widespread interest as an inhibitor of the Na/K-ATPase enzyme, which facilitates an increase in intracellular calcium concentration, consequently improving cardiac function. Although primarily targeted for the treatment of heart failure, atrial fibrillation, and assorted cardiac arrhythmias, Digoxin's effectiveness and low-cost nature has garnered it significant acclaim since its first approval by GSK Plc in 1954, and continues to be prescribed frequently despite its age. However, caution must be exercised due to its slender therapeutic window and propensity for toxicity, necessitating frequent and thorough monitoring of patients taking Digoxin by their healthcare provider. Click on the image below to begin the exploration journey of Digoxin through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Sensorion's Phase 2a Trial: SENS-401 Meets Primary Objective in Hearing Preservation
Latest Hotspot
3 min read
Sensorion's Phase 2a Trial: SENS-401 Meets Primary Objective in Hearing Preservation
12 March 2024
Sensorion Reveals Achievement of Main Goal in Phase 2a Trial of SENS-401 for Preserving Remaining Hearing Function.
Read →
Latest Advances and Applications of Bispecific Antibodies in Cancer Treatment
Hot Spotlight
15 min read
Latest Advances and Applications of Bispecific Antibodies in Cancer Treatment
12 March 2024
On March 6th, Nature Reviews Drug Discovery highlighted recent bispecific antibodies (bsAbs) progress in cancer therapy.
Read →
Celltrion USA Submits Biosimilar Licensing Application for CT-P39, an Alternative to XOLAIR
Latest Hotspot
3 min read
Celltrion USA Submits Biosimilar Licensing Application for CT-P39, an Alternative to XOLAIR
12 March 2024
Celltrion USA has finalized their application for a biologic license to the U.S. Food and Drug Administration for CT-P39, their alternative biosimilar to XOLAIR (omalizumab).
Read →
Strategically Search Phenazopyridine on Synapse: A How-to Guide
Drug Insights
2 min read
Strategically Search Phenazopyridine on Synapse: A How-to Guide
12 March 2024
Phenazopyridine, a diminutive molecule, serves primarily as an analgesic agent for urinary tract pain.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.